CILTISTOTUG
UNII G2CB897733

Substance Identification & Data

This profile provides standardized clinical and technical data for Ciltistotug, uniquely identified by the FDA Unique Ingredient Identifier (UNII) G2CB897733.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3014361-59-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

G2CB897733

CAS Registry Number

3014361-59-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CILTISTOTUG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C178347

National Cancer Institute reference terminology for clinical and research data.

INN ID

13467

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-38

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ciltistotug. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CILTISTOTUG

Common Names & Synonyms

CILTISTOTUG [INN]

CILTISTOTUG [USAN]

H-GAMMA2 HEAVY CHAIN (1-441) (VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV1-47-14*01 (84.7%) -(IGHD) -IGHJ2*01 (100%)/HOMO SAPIENS IGHV1-2*02 (79.6%) -(IGHD) -IGHJ6*01 (90.9%) V124>L (111), CDR-IMGT (8.8.8) (26-33.51-58.97-104)) (1-115) -HOMO SAPIENS IGHG2*01 G2M.. (100%) CH2 V45.1 (CH1 (116-213), HINGE 1-12 (214-225), CH2 V45.1 (276) (226-334), CH3 (335-439), CHS (440-441)) (116-441)), (129-219')-DISULFIDE WITH L-KAPPA LIGHT CHAIN (1'-219') (V-KAPPA MUSMUS/HOMSAP (MUS MUSCULUS IGKV1-110*01 (88.0%) -IGKJ1*01 (91.7%) L124>V (109')/HOMO SAPIENS IGKV2-30*02 (88.0%) -IGKJ4*01 (100%), CDR-IMGT (11.3.9) (27'-37'.55'-57'.94'-102')) (1'-112') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (158'), V101 (196')) (113'-219')); DIMER (217-217'':218-218'':221-221'':224-224'')-TETRAKISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

IMMUNOGLOBULIN G2, ANTI-(HUMAN/MACACA MULATTA CD40 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL YH003 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL YH003 .KAPPA.-CHAIN, DIME

IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS CD40 (TNFRSF5, TUMOR NECROSIS FACTOR RECEPTOR (TNFR) SUPERFAMILY MEMBER 5, P50)), MONOCLONAL ANTIBODY

YH 003 [WHO-DD]

YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)